Psynomics is the first and only company in the world to offer DNA-based diagnostic and therapeutic tests with which to help millions of people suffering from bipolar disorder.
Psynomics is based in San Diego, California, one of the nation’s leading biotech regions and home to internationally-renowned medical organizations such as the Salk Institute, the University of California San Diego (UCSD) and the Scripps Research Institute.
The company was founded on the work of two UCSD scientists who are among the world’s top experts in clinical psychiatry, molecular genetics and neuropsychiatric genomics research. Through the company’s relationship with UCSD, Psynomics’ scientists discovered and patented eight novel genes linked to mental illness, with one primary gene, known as GRK3, for bipolar disorder.
Psynomics’ vision is to maintain its position as the world's leading provider of DNA-based tools for the diagnosis and treatment of mental illnesses.